Generic Names for Brand Name Medications
Thorazine is the brand name for chlorpromazine, and Adderall is the brand name for mixed amphetamine salts (specifically a 3:1 ratio mixture of dextroamphetamine to levoamphetamine salts). 1, 2
Thorazine (Chlorpromazine)
Chlorpromazine is a first-generation (typical) antipsychotic medication that was introduced in the 1950s and revolutionized the treatment of schizophrenia 3. It belongs to the phenothiazine class of antipsychotics and is characterized as a low-potency agent, meaning it requires higher doses to achieve dopamine receptor blockade compared to high-potency agents like haloperidol 4.
Key characteristics:
- Mechanism: Primarily blocks dopamine receptors, with significant anticholinergic, antihistaminic, and alpha-adrenergic blocking properties
- Side effect profile: Due to its low potency, chlorpromazine tends to cause more sedation and anticholinergic effects (dry mouth, constipation, urinary retention, cognitive impairment) rather than extrapyramidal symptoms 1, 4
- Additional concerns: Can cause orthostatic hypotension, may prolong QTc interval, and parenteral use may cause local irritation 1
Adderall (Mixed Amphetamine Salts)
Adderall contains a specific formulation of mixed amphetamine salts in a 3:1 ratio of dextroamphetamine to levoamphetamine 2, 5. The FDA-approved formulation includes four salts: dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate 2.
Key characteristics:
- Mechanism: Inhibits dopamine and norepinephrine transporters, vesicular monoamine transporter 2, and monoamine oxidase activity, thereby enhancing prefrontal cortex efficiency and optimizing executive and attentional function 6
- Formulations: Available as immediate-release (IR) tablets and extended-release (XR) capsules, with the XR formulation providing approximately 12 hours of coverage through a dual-bead system 7, 8
- Clinical use: First-line pharmacotherapy for ADHD in children (age 6 and older), adolescents, and adults 9, 6, 10
Important clinical considerations for amphetamines:
- Rapid onset of action (within 1.5 hours for extended-release formulations) 7
- Dose-proportional pharmacokinetics with body weight as a fundamental determinant of plasma concentrations 5
- Children exhibit shorter plasma half-life (
7 hours) compared to adults (10-12 hours) 5 - Common adverse effects include decreased appetite, insomnia, irritability, increased blood pressure and heart rate 6